Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Advertisement

British Journal of Cancer
  • View all journals
  • Search
  • My Account Login
  • Content Explore content
  • About the journal
  • Publish with us
  • Sign up for alerts
  • RSS feed
  1. nature
  2. british journal of cancer
  3. regular article
  4. article
The 121 amino acid isoform of vascular endothelial growth factor is more strongly tumorigenic than other splice variants in vivo
Download PDF
Download PDF
  • Regular Article
  • Open access
  • Published: 06 June 2000

The 121 amino acid isoform of vascular endothelial growth factor is more strongly tumorigenic than other splice variants in vivo

  • H-T Zhang1,
  • P A E Scott2,
  • L Morbidelli3,
  • S Peak4,
  • J Moore1,
  • H Turley5,
  • A L Harris1,
  • M Ziche6 &
  • …
  • R Bicknell1 

British Journal of Cancer volume 83, pages 63–68 (2000)Cite this article

  • 1922 Accesses

  • 127 Citations

  • 6 Altmetric

  • Metrics details

This article has been updated

Abstract

Vascular endothelial growth factor (VEGF) is known to occur as at least six differentially spliced variants, giving rise to mature isoforms containing 121, 145, 165, 183, 189 and 206 amino acids. However, little is yet known concerning the in vivo activities of this differential splicing. Stably transfected MCF-7 breast carcinoma cells were constructed that secreted comparable amounts of the 121, 165 or 189 isoforms. Rabbit corneal angiogenesis assays showed the VEGF121 transfectant to have much greater angiogenic activity than the 165 or 189 expressing MCF-7 cells. While the VEGF121-expressing MCF-7 cells were reproducibly more tumorigenic than the control transfectants, this was not the case with the VEGF165- or VEGF189-expressing cells. More surprising was the observation that VEGF189 located to the nucleus, consistent with the presence of a highly conserved nuclear localization sequence in exon 6a that is expressed in VEGF189 but not 121 or 165. It was concluded that the VEGF121 isoform is both more angiogenic and tumorigenic than are the 165 and 189 isoforms. This is probably due to the ability of the 121 isoform, unlike the 165 and 189 isoforms, to freely diffuse from the cells producing it. © 2000 Cancer Research Campaign

Similar content being viewed by others

TARDBP promotes ovarian cancer progression by altering vascular endothelial growth factor splicing

Article 11 November 2022

Biology and therapeutic targeting of vascular endothelial growth factor A

Article 25 July 2023

Neutralization of the induced VEGF-A potentiates the therapeutic effect of an anti-VEGFR2 antibody on gastric cancer in vivo

Article Open access 23 July 2021

Article PDF

Change history

  • 16 November 2011

    This paper was modified 12 months after initial publication to switch to Creative Commons licence terms, as noted at publication

References

  • Acland P, Dixon M, Peters G and Dickson C (1990) Subcellular fate of the int-2 oncoprotein is determined by choice of initiation codon. Nature 343: 662–665

    Article  CAS  Google Scholar 

  • Bader T and Wiezerbin J (1994) Nuclear accumulation of interferon-γ. Proc Natl Acad Sci USA 91: 11831–11835

    Article  CAS  Google Scholar 

  • Bicknell R (1997) Mechanistic insights into tumour angiogenesis. In: Tumour Angiogenesis, Bicknell R, Lewis CE, Ferrara N (eds), pp. 19–28. Oxford University Press: Oxford

    Google Scholar 

  • Carmeliet P, Ng Y-S, Nuyens D, Theilmeier G, Brusselmans K, Cornelissen I, Ehler E, Kakkar VV, Stalmans I, Mattot V, Perriard J-C, Dewerchin M, Flameng W, Nagy A, Lupu F, Moons L, Collen D, D’Amore PA and Shima DT (1999) Impaired myocardial angiogenesis and ischemic cardiomyopathy in mice lacking the vascular endothelial growth factor isoforms VEGF164 and VEGF188. Nature Med 5: 495–502

    Article  CAS  Google Scholar 

  • Cheung N, Wong MP, Yuen ST, Leung SY and Chung LP (1998) Tissue-specific expression pattern of vascular endothelial growth factor isoforms in the malignant transformation of lung and colon. Hum Pathol 29: 911–914

    Article  Google Scholar 

  • Coltrini D, Gualandris A and Nelli EE (1995) Growth advantage and vascularisation induced by basic fibrolblast growth factor overexpression in endometrial HEC-1-B cells: An export -dependent mechanism of action. Cancer Res 55: 4729–4738

    CAS  PubMed  Google Scholar 

  • Gimbrone MA Jr, Cotran RS, Leapman SB and Folkman J (1974) Tumor growth and neovascularisation: an experimental model using the rabbit cornea. J Natl Cancer Inst 52: 413–427

    Article  Google Scholar 

  • Gitay-Goren H, Cohen T, Tessler S, Soker S, Gengrinovitch S, Rockwell P, Klagsbrun M, Levi BZ and Neufeld G (1996) Selective binding of VEGF121 to one of the three vascular endothelial growth factor receptors of vascular endothelial cells. J Biol Chem 271: 5519–5523

    Article  CAS  Google Scholar 

  • Grutzkau A, Kruger-Krasagakes S, Baumeister H, Schwarz C, Kogel H, Welker P, Lippert U, Henz BM and Moller A (1998) Synthesis, storage and release of vascular endothelial growth factor/vascular permeability factor (VEGF/VPF) by human mast cells: implications for the biological significance of VEGF206. Mol Biol Cell 9: 875–884

    Article  CAS  Google Scholar 

  • Houck KA, Ferrara N, Winer J, Cachianes G, Li B and Leung DW (1991) The vascular endothelial growth factor family: identification of a fourth molecular species and characterisation of alternative splicing of RNA. Mol Endocrinol 5: 1806–1814

    Article  CAS  Google Scholar 

  • Houck KA, Leung DW, Rowland AM, Winer J and Ferrara N (1992) Dual regulation of vascular endothelial growth factor bioavailability genetic and proteolytic mechanisms. J Biol Chem 267: 26031–26037

    CAS  PubMed  Google Scholar 

  • Keyt BA, Berleau LT, Nguyen HV, Chen H, Heinsohn H, Vandlen R and Ferrara N (1996) The carboxyl-terminal domain (111–165) of vascular endothelial growth factor is critical for its mitogenic potency. J Biol Chem 271: 7788–7795

    Article  CAS  Google Scholar 

  • Lei J, Jiang A and Pei D (1998) Identification and characterisation of a new splicing variant of vascular endothelial growth factor: VEGF183. Biochim Biophys Acta 1443: 400–406

    Article  CAS  Google Scholar 

  • Neufeld G, Cohen T, Gengrinovitch S and Poltorak Z (1999) Vascular endothelial growth factor and its receptors. FASEB J 13: 9–22

    Article  CAS  Google Scholar 

  • Park JE, Keller GA and Ferrara N (1993) The vascular endothelial growth factor (VEGF) isoforms: differential deposition into the subepithelial extracellular matrix and bioactivity of extracellular matrix-bound VEGF. Mol Biol Cell 4: 1317–1326

    Article  CAS  Google Scholar 

  • Relf M, LeJeune S, Scott PAE, Fox S, Smith K, Leek R, Moghaddam A, Whitehouse R, Bicknell R and Harris AL (1997) Expression of the angiogenic factors vascular endothelial cell growth factor, acidic and basic fibroblast growth factor, transforming growth factor β-1, platelet-derived endothelial cell growth factor, placenta growth factor and pleiotrophin in human primary breast cancer and its relation to angiogenesis. Cancer Res 57: 963–969

    CAS  PubMed  Google Scholar 

  • Robbins J, Dilworth SM, Laskey RA and Dingwall C (1991) Two independent basic domains in nucleoplasmin nuclear targeting sequence: Identification of a class of bipartite nuclear targeting sequence. Cell 64: 615–623

    Article  CAS  Google Scholar 

  • Siemeister G, Schnurr B, Mohrs K, Schachtele C, Marme D and Martiny-Baron G (1996) Expression of biologically active isoforms of the tumor angiogenesis factor VEGF in Escherichia coli. Biochem Biophys Res Commun 222: 249–255

    Article  CAS  Google Scholar 

  • Smith K, Houlbrook S, Greenall M, Carmichael J and Harris AL (1993) Topoisomerase IIα coamplification with erbB-2 in human primary breast cancer and breast cancer cell lines: relationship to m-AMSA and mitoxantrone sensitivity. Oncogene 8: 933–938

    CAS  PubMed  Google Scholar 

  • Tischer E, Mitchell R, Hartman T, Silva M, Gospodarwicz D, Fiddes JC and Abraham JA (1991) The human gene for vascular endothelial growth factor. Multiple protein forms are encoded through alternative exon splicing. J Biol Chem 266: 11947–11954

    CAS  Google Scholar 

  • Turley H, Scott PAE, Watts VM, Bicknell B, Harris AL and Gatter KG (1998) Expression of VEGF in routinely fixed material using a new monoclonal antibody VG1. J Pathol 186: 313–318

    Article  CAS  Google Scholar 

  • Zhang H, Craft P, Scott PAE, Ziche M, Weich HA, Harris AL and Bicknell R (1995) Enhancement of tumor growth and vascular density by transfection of vascular endothelial cell growth factor into MCF-7 human breast carcinoma cells. J Natl Cancer Inst 87: 213–219

    Article  CAS  Google Scholar 

  • Ziche M, Morbidelli L, Masini E, Amerini S, Granger HJ, Maggi CA, Geppetti P and Ledda F (1994) Nitric oxide mediates angiogenesis in vivo and endothelial cell growth and migration in vitro promoted by substance P. J Clin Invest 94: 2036–2044

    Article  CAS  Google Scholar 

  • Ziche M, Morbidelli L, Choudhuri R, Zhang H-T, Donnini S, Granger HJ and Bicknell R (1997) Nitric oxide-synthase lies downstream of vascular endothelial growth factor but not basic fibroblast growth factor induced angiogenesis. J Clin Invest 99: 2625–2634

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Molecular Angiogenesis Laboratory, Imperial Cancer Research Fund, Institute of Molecular Medicine, University of Oxford, John Radcliffe Hospital, Oxford, UK

    H-T Zhang, J Moore, A L Harris & R Bicknell

  2. Department of Oncology, Christchurch Hospital, Christchurch, New Zealand

    P A E Scott

  3. Department of Pharmacology, University of Florence, Florence, Italy

    L Morbidelli

  4. Clare Hall Laboratories, Imperial Cancer Research Fund, South Mimms, Herts, UK

    S Peak

  5. Department of Cellular Science, University of Oxford, John Radcliffe Hospital, Oxford, UK

    H Turley

  6. Institute of Pharmacological Science, School of Pharmacy, University of Siena, Via Piccolomini 170, Siena, 53100, Italy

    M Ziche

Authors
  1. H-T Zhang
    View author publications

    Search author on:PubMed Google Scholar

  2. P A E Scott
    View author publications

    Search author on:PubMed Google Scholar

  3. L Morbidelli
    View author publications

    Search author on:PubMed Google Scholar

  4. S Peak
    View author publications

    Search author on:PubMed Google Scholar

  5. J Moore
    View author publications

    Search author on:PubMed Google Scholar

  6. H Turley
    View author publications

    Search author on:PubMed Google Scholar

  7. A L Harris
    View author publications

    Search author on:PubMed Google Scholar

  8. M Ziche
    View author publications

    Search author on:PubMed Google Scholar

  9. R Bicknell
    View author publications

    Search author on:PubMed Google Scholar

Rights and permissions

From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/

Reprints and permissions

About this article

Cite this article

Zhang, HT., Scott, P., Morbidelli, L. et al. The 121 amino acid isoform of vascular endothelial growth factor is more strongly tumorigenic than other splice variants in vivo. Br J Cancer 83, 63–68 (2000). https://doi.org/10.1054/bjoc.2000.1279

Download citation

  • Received: 20 October 1999

  • Revised: 15 February 2000

  • Accepted: 19 February 2000

  • Published: 06 June 2000

  • Issue date: 01 July 2000

  • DOI: https://doi.org/10.1054/bjoc.2000.1279

Share this article

Anyone you share the following link with will be able to read this content:

Sorry, a shareable link is not currently available for this article.

Provided by the Springer Nature SharedIt content-sharing initiative

Keywords

  • vascular endothelial growth factor
  • angiogenesis
  • tumorigenesis
  • differential splicing
  • nuclear localization

This article is cited by

  • How VEGF-A and its splice variants affect breast cancer development – clinical implications

    • Hivin Al Kawas
    • Inas Saaid
    • Maria Margarete Karsten

    Cellular Oncology (2022)

  • Expression of vascular endothelial growth factor (VEGF) in equine sarcoid

    • Manuela Martano
    • Karen Power
    • Paola Maiolino

    BMC Veterinary Research (2018)

  • High expression of a novel splicing variant of VEGF, L-VEGF144 in glioblastoma multiforme is associated with a poorer prognosis in bevacizumab treatment

    • Wen-Yu Cheng
    • Chiung-Chyi Shen
    • Jun-Peng Chen

    Journal of Neuro-Oncology (2018)

  • MDA-MB-231 breast cancer cells overexpressing single VEGF isoforms display distinct colonisation characteristics

    • Melanie Di Benedetto
    • Aurore Toullec
    • Martine Perrot-Applanat

    British Journal of Cancer (2015)

  • Overexpression of VEGF183 promotes murine breast cancer cell proliferation in vitro and induces dilated intratumoral microvessels

    • Huiyong Zhang
    • Ying Chen
    • Wuling Zhu

    Tumor Biology (2015)

Download PDF

Advertisement

Explore content

  • Research articles
  • Reviews & Analysis
  • News & Comment
  • Current issue
  • Collections
  • Follow us on Twitter
  • Sign up for alerts
  • RSS feed

About the journal

  • Journal Information
  • Open access publishing
  • About the Editors
  • Contact
  • Special Issues
  • For Advertisers
  • Subscribe

Publish with us

  • For Authors & Referees
  • Language editing services
  • Submit manuscript

Search

Advanced search

Quick links

  • Explore articles by subject
  • Find a job
  • Guide to authors
  • Editorial policies

British Journal of Cancer (Br J Cancer)

ISSN 1532-1827 (online)

ISSN 0007-0920 (print)

nature.com sitemap

About Nature Portfolio

  • About us
  • Press releases
  • Press office
  • Contact us

Discover content

  • Journals A-Z
  • Articles by subject
  • protocols.io
  • Nature Index

Publishing policies

  • Nature portfolio policies
  • Open access

Author & Researcher services

  • Reprints & permissions
  • Research data
  • Language editing
  • Scientific editing
  • Nature Masterclasses
  • Research Solutions

Libraries & institutions

  • Librarian service & tools
  • Librarian portal
  • Open research
  • Recommend to library

Advertising & partnerships

  • Advertising
  • Partnerships & Services
  • Media kits
  • Branded content

Professional development

  • Nature Awards
  • Nature Careers
  • Nature Conferences

Regional websites

  • Nature Africa
  • Nature China
  • Nature India
  • Nature Japan
  • Nature Middle East
  • Privacy Policy
  • Use of cookies
  • Legal notice
  • Accessibility statement
  • Terms & Conditions
  • Your US state privacy rights
Springer Nature

© 2025 Springer Nature Limited